Rheumatoid Arthritis

Researchers suggested that anti-oxidants such as Vitamin C and E could delay or even reduce the risk of AMD in patients with gout, as they have been proven to have a beneficial effect in patients with AMD.

Daily upadacitinib monotherapy 15 mg/30 mg met both primary endpoints with 52%/56% of methotrexate patients achieving ACR50 at week 12 and 48%/50% achieving clinical remission at week 24.

After rejecting the drug in 2017, the FDA approved the 2 mg dose of baricitinib (Olumiant) for adults with moderate to severe rheumatoid arthritis.

Upon unearthing rheumatoid arthritis’ epigenome, researchers at University of California San Diego School of Medicine and the Icahn School of Medicine at Mount Sinai have also discovered an overlap between the causes of rheumatoid arthritis and Huntington’s disease.

The BLA was originally accepted by the FDA for review in September 2017, with the product intended to be used for the treatment of immunological conditions such as rheumatoid arthritis, as well as blood cancers.

The committee recommends the approval of baricitinib 2-mg, but not 4-mg; this comes a year after baricitinib was rejected by the FDA.

Upadacitinib (15 mg, once-daily) met both primary endpoints, with 71% of patients achieving ACR20 and 29% achieving clinical remission at week 12.

This morning, AbbVie revealed positive top-line results from the Phase 3 SELECT-COMPARE clinical trial evaluating upadacitinib in rheumatoid arthritis.

This morning, Novartis announced that the U.S. FDA has accepted its Biologics License Application for the proposed biosimilar adalimumab to the reference medicine, Humira, developed by AbbVie, Inc.

The Biologics License Application is for another biosimilar to AbbVie's best-selling Humira drug.

The monotherapy resulted in LDA by week 14 in both the 15 mg (45%) and 30 mg (53%) groups.

Improvement in DAS28 scores was statistically significant in 26% of patients using adalimumab every 3 weeks compared to every 2 weeks.

The response letter indicated the need for additional clinical data in order to further evaluate sirukumab's safety profile.

The long-term study shows biosimilar adalimumab, if approved, will further improve access to treatment for immunological diseases.

The study showed positive results in a difficult-to-treat patient population.

The Arthritis Advisory Committee unanimously supported the drug’s efficacy data, but not it’s safety profile.

Everything the clinician needs to stay connected.

In a letter to the company, the FDA cited safety and dosage concerns as major factors in their decision.

The drug is now approved for psoriatic arthritis treatment in adults.

The drug helped patients achieve clinical remission, low disease activity.

Sarilumab would be able to treat adult patients with moderately-to-severely active rheumatoid arthritis who cannot tolerate one or more disease modifying antirheumatic drugs like methotrexate.

This is the first FDA-approved therapy specific to this form of vasculitis.

At AAPA 2017, Benjamin Smith, PA-C, DFAAPA, Florida State University College of Medicine, discussed the tremendous advances in both treating and diagnosing rheumatoid arthritis. About 15 years ago, the CCP lab tests came about, which certainly help with specificity for diagnosing rheumatoid arthritis (RA).

Arthritis may soon be combated by rewired stem cells.

FDA to consider Xeljanz, the sole JAK inhibitor available in US, for new indication.

Infliximab-abda approved for range of gastroenterological and rheumatoid conditions.

At one year, nearly as many on monotherapy were in remission as on combo therapy.

Company hopes former RA candidate will be approved for rare blood condition.

Prolonged, repetitive hard work is a risk factor for RA, according to a new study.

FDA rejects potential blockbuster, requesting further safety data.